287 related articles for article (PubMed ID: 26032639)
1. Nicotinic modulation of auditory evoked potential electroencephalography in a rodent neurodevelopmental model of schizophrenia.
Kohlhaas KL; Robb HM; Roderwald VA; Rueter LE
Biochem Pharmacol; 2015 Oct; 97(4):482-487. PubMed ID: 26032639
[TBL] [Abstract][Full Text] [Related]
2. Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization.
Radek RJ; Robb HM; Stevens KE; Gopalakrishnan M; Bitner RS
J Pharmacol Exp Ther; 2012 Dec; 343(3):736-45. PubMed ID: 22988063
[TBL] [Abstract][Full Text] [Related]
3. Auditory sensory processing deficits in sensory gating and mismatch negativity-like responses in the social isolation rat model of schizophrenia.
Witten L; Oranje B; Mørk A; Steiniger-Brach B; Glenthøj BY; Bastlund JF
Behav Brain Res; 2014 Jun; 266():85-93. PubMed ID: 24613239
[TBL] [Abstract][Full Text] [Related]
4. Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.
Hashimoto K
Curr Pharm Des; 2015; 21(26):3797-806. PubMed ID: 26044974
[TBL] [Abstract][Full Text] [Related]
5. Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials.
Siegel SJ; Maxwell CR; Majumdar S; Trief DF; Lerman C; Gur RE; Kanes SJ; Liang Y
Neuroscience; 2005; 133(3):729-38. PubMed ID: 15908134
[TBL] [Abstract][Full Text] [Related]
6. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia.
Moore H; Jentsch JD; Ghajarnia M; Geyer MA; Grace AA
Biol Psychiatry; 2006 Aug; 60(3):253-64. PubMed ID: 16581031
[TBL] [Abstract][Full Text] [Related]
7. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR
Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075
[TBL] [Abstract][Full Text] [Related]
8. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.
Hamilton HK; D'Souza DC; Ford JM; Roach BJ; Kort NS; Ahn KH; Bhakta S; Ranganathan M; Mathalon DH
Schizophr Res; 2018 Jan; 191():87-94. PubMed ID: 28711472
[TBL] [Abstract][Full Text] [Related]
9. Memory deficits with intact cognitive control in the methylazoxymethanol acetate (MAM) exposure model of neurodevelopmental insult.
O'Reilly KC; Perica MI; Fenton AA
Neurobiol Learn Mem; 2016 Oct; 134 Pt B(Pt B):294-303. PubMed ID: 27485950
[TBL] [Abstract][Full Text] [Related]
10. Aberrant high frequency oscillations recorded in the rat nucleus accumbens in the methylazoxymethanol acetate neurodevelopmental model of schizophrenia.
Goda SA; Olszewski M; Piasecka J; Rejniak K; Whittington MA; Kasicki S; Hunt MJ
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Aug; 61():44-51. PubMed ID: 25862088
[TBL] [Abstract][Full Text] [Related]
11. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats.
Hajós M; Hurst RS; Hoffmann WE; Krause M; Wall TM; Higdon NR; Groppi VE
J Pharmacol Exp Ther; 2005 Mar; 312(3):1213-22. PubMed ID: 15523001
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.
Potasiewicz A; Nikiforuk A; Hołuj M; Popik P
J Psychopharmacol; 2017 Feb; 31(2):260-271. PubMed ID: 28168926
[TBL] [Abstract][Full Text] [Related]
13. Nicotine effect on mismatch negativity in smoking and nonsmoking patients with schizophrenia.
Inami R; Kirino E
Schizophr Res; 2019 Jun; 208():496-497. PubMed ID: 30630703
[No Abstract] [Full Text] [Related]
14. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
[TBL] [Abstract][Full Text] [Related]
15. MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs.
Mar AC; Nilsson SRO; Gamallo-Lana B; Lei M; Dourado T; Alsiö J; Saksida LM; Bussey TJ; Robbins TW
Psychopharmacology (Berl); 2017 Oct; 234(19):2837-2857. PubMed ID: 28744563
[TBL] [Abstract][Full Text] [Related]
16. Effects of nicotine vary across two auditory evoked potentials in the mouse.
Metzger KL; Maxwell CR; Liang Y; Siegel SJ
Biol Psychiatry; 2007 Jan; 61(1):23-30. PubMed ID: 16497274
[TBL] [Abstract][Full Text] [Related]
17. Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma.
Phillips JM; Ehrlichman RS; Siegel SJ
Neuroscience; 2007 Feb; 144(4):1314-23. PubMed ID: 17184927
[TBL] [Abstract][Full Text] [Related]
18. Acute separate and combined effects of cannabinoid and nicotinic receptor agonists on MMN-indexed auditory deviance detection in healthy humans.
de la Salle S; Inyang L; Impey D; Smith D; Choueiry J; Nelson R; Heera J; Baddeley A; Ilivitsky V; Knott V
Pharmacol Biochem Behav; 2019 Sep; 184():172739. PubMed ID: 31283908
[TBL] [Abstract][Full Text] [Related]
19. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
Feuerbach D; Lingenhoehl K; Olpe HR; Vassout A; Gentsch C; Chaperon F; Nozulak J; Enz A; Bilbe G; McAllister K; Hoyer D
Neuropharmacology; 2009 Jan; 56(1):254-63. PubMed ID: 18793655
[TBL] [Abstract][Full Text] [Related]
20. The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.
Bristow LJ; Easton AE; Li YW; Sivarao DV; Lidge R; Jones KM; Post-Munson D; Daly C; Lodge NJ; Gallagher L; Molski T; Pieschl R; Chen P; Hendricson A; Westphal R; Cook J; Iwuagwu C; Morgan D; Benitex Y; King D; Macor JE; Zaczek R; Olson R
PLoS One; 2016; 11(7):e0159996. PubMed ID: 27467081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
